24100-18-3

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-3-METHOXYPYRIDINE is used as a synthetic intermediate for the preparation of triazolopyrimidine derivatives and analogs. These compounds are known to function as inhibitors of AXL receptor tyrosine kinase, which plays a crucial role in various cellular processes, including cell survival, migration, and invasion. Inhibition of AXL receptor tyrosine kinase has been shown to have potential therapeutic applications in the treatment of various diseases, such as cancer and fibrosis.

InChI:InChI=1/C6H6BrNO/c1-9-5-3-2-4-8-6(5)7/h2-4H,1H3

Upstream product

• 6602-32-0 2-bromo-pyridin-3-ol 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 109-00-2 3-HYDROXYPYRIDINE 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 186581-53-3 diazomethane 

Downstream Products

• 73282-13-0 1,1'-bis-benzenesulfonyl-1H,1'H-[2,2']biindolyl 
• 7295-76-3 3-methoxypyridine 
• 93560-59-9 3,3'-dimethoxy-2,2'-bipyridine 
• 10201-71-5 3-methoxypyridin-2-amine 
• 52605-97-7 2,3-dimethoxypyridine 
• 104819-48-9 2-bromo-3-methoxypyridine N-oxide 
• 76066-07-4 2-bromo-3-methoxy-6-nitropyridine 
• 946844-56-0 3-methoxy-2-(2-vinylphenyl)pyridine 
• 105170-27-2 2-bromo-5-methoxypyridine 
• 22187-96-8 5-methoxy-2-pyridinecarboxaldehyde 
• 10167-97-2 2-amino-5-methoxypyridine 
• 325796-84-7 1‐(5‐methoxypyridin‐2‐yl)ethan‐1‐one 
• 325796-76-7 1-Benzyl-3-(5-methoxypyridin-2-ylmethyl)-1H-indol 
• 325796-79-0 1-Benzyl-3-(5-methoxypyridin-2-ylmethyl)-2,3-dihydro-1H-indol 

Relevant academic research and scientific papers

Preparation method of 2-bromo-3-methoxypyridine

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of 2-bromine-3-methoxypyridine, which comprises the following reaction steps: (1) preparation of 2-bromine-3-hydroxypyridine, and (2) preparation of 2-bromine-3-methoxypyridine: cooling the sodium hydroxide aqueous solution to -10 DEG C to 0 DEG C by using an ice salt bath, and dropwise adding liquid bromine within the temperature range, dissolving 3-hydroxypyridine in a sodium hydroxide aqueous solution, dropwise adding the solution into the liquid bromine solution, and keepingthe system temperature at 10-15 DEG C, after dropwise adding, stirring the mixed solution for 2.5-3 hours at room temperature, and then adjusting the pH value to 7 by using acid; and recrystallizing the obtained crude product to obtain the 2-bromo-3-hydroxypyridine. The method has the beneficial effects of mild reaction conditions, short route and high yield.

A 2 - bromo -3 - methoxy pyridine preparation method

The invention belongs to the field of organic synthetic technology, in particular to a 2 - bromo - 3 - methoxy pyridine of the preparation method, the reaction steps are as follows: (1) 2 - bromo - 3 - hydroxy pyridine, (2) 2 - bromo - 3 - methoxy pyridine; ice salt bath for the aqueous sodium hydroxide solution cooled to - 10 - 0 °C, in this temperature range, [...]; the 3 - hydroxy pyridine dissolved in the sodium hydroxide solution, then the solution is dropped to the above bromine solution, to maintain the system temperature is 10 - 15 °C; drops, room temperature stirring 2.5 - 3 hours, then use acid to adjust pH to 7; the resulting crude product recrystallized, to 2 - bromo - 3 - hydroxy pyridine. The beneficial effect of the invention is: mild reaction conditions, route is short, high yield.

Iridium(iii) complex-based electrochemiluminescent probe for H2S

Since abnormal levels of hydrogen sulphide (H2S) correlate with various diseases, simple methods for its rapid and sensitive detection are highly required. Herein, we introduce a new electrochemiluminescent probe 1 for H2S based on a cyclometalated iridium(iii) complex. o-(Azidomethyl)benzoate ester groups on the main ligands of probe 1 react selectively with H2S, resulting in cascade reactions involving H2S-mediated reduction and intramolecular cyclization/ester cleavage. With this structural change induced by H2S, the intrinsic electrochemiluminescence (ECL) of 1 decreased greatly due to the unfavourable electron transfer of a tripropylamine (TPA) radical. Probe 1 showed a high ECL turn-off ratio and good selectivity for H2S over various anions and biothiols. The sensing mechanism of H2S was elucidated using1H NMR spectroscopy and MALDI-TOF mass spectrometry analyses.

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID

A compound effective as a probe targeting amyloid for image diagnosis and a reagent comprising the compound for detecting amyloid deposited on a biological tissue are provided. Provided are a compound represented by the following formula (1): wherein R1, R2 and R3 independently represent a group selected from the group consisting of a hydrogen, hydroxyl group, alkyl substituent with 1 to 4 carbon atoms, alkoxy substituent having alkyl chain with 1 to 4 carbon atoms and halogen substituent, excluding the case where two or more of the substituents R1, R2 and R3 are hydrogen, R4 is a group selected from the group consisting of a hydrogen, hydroxy group, alkoxy substituent having alkyl chain with 1 to 4 carbon atoms and halogen substituent, and m is an integer of 1 to 4, provided that at least one of R1, R2, R3 and R4 represents a radioactive halogen substituent, and a reagent comprising the same.

NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID

A compound effective as a probe targeting amyloid for image diagnosis and a reagent comprising the compound for detecting amyloid deposited on a biological tissue are provided. Provided are a compound represented by the following formula (1): wherein R1 is a group selected from the group consisting of a halogen substituent, alkyl substituent with 1 to 4 carbon atoms, alkoxy substituent having alkyl chain with 1 to 4 carbon atoms and hydroxyl group, R2 is a group selected from the group consisting of a cyano substituent, alkyl substituent with 1 to 4 carbon atoms and halogen substituent, is a group selected from the group consisting of a hydroxyl group, halogen substituent and substituent represented by the following formula: (wherein R4 is a hydrogen, halogen substituent or hydroxyl group, and m is an integer of 1 to 4), provided that a t least one of R1, R2, R3 and R4 represents a radioactive halogen, and a reagent comprising the same.

USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME

The invention provides a reagent for detecting amyloid in a biological tissue which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagenicity. The reagent for detecting amyloid deposited in a biological tissue comprises the compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or a nitrogen, and R3 is a group represented by the following formula: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A3, A3 and A4 represents a carbon, and R5 binds to a carbon represented by A1, A2, A3 or A4.

NOVEL COMPOUND HAVING AFFINITY TO AMYLOID

The invention relates to a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagenicity, and also relates to a low-toxic diagnostic agent for Alzheimer's disease containing the compound. The compound is represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or a nitrogen, and R3 is a group represented by the following formula: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R3 binds to a carbon represented by A1, A2, A3 or A4.

NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID

A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.

NOVEL COMPOUNDS WITH AFFINITY FOR AMYLOID

It is intended to provide a compound effective as an image diagnosis probe targeting amyloid and a diagnostic agent for Alzheimer's disease comprising the compound. Provided is a compound represented by the following formula or a salt thereof: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen, R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms and alkoxy substituents with 1-4 carbon atoms, and R3 is a radioactive halogen substituent, provided that at least one of A1 A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4, as well as a diagnostic agent for Alzheimer's disease comprising the compound represented by the above formula or a salt thereof.